Lysogene appoints Céline Fantin and Michel Picot to its Board of Directors

– FRANCE, Paris –  Lysogene (EPA: LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced the co-optations of Céline Fantin and Michel Picot to its Board of Directors, replacing Philippe Goupit and Mathieu Simon who are leaving the Board.
Céline Fantin will bring a new contribution to Lysogene with her expertise in audit and transformation programs in the pharmaceutical industry. Michel Picot will also provide Lysogene with his extensive financing and strategy experience.
“We are very pleased to announce the appointment of a renewed Board of Directors at Lysogene, which reflects the new momentum in place within the Company. We wanted a tighter, action-oriented Board of Directors adapted to the current situation of Lysogene. Céline Fantin and Michel Picot have extensive experience in audit, financing, and strategy in the pharmaceutical sector, which will be valuable assets to enable Lysogene to face its current challenges and support its ambitions” said Chairman and CEO, Karen Aiach, Founder. 
Michel Picot and Céline Fantin join the Audit Committee, respectively as Chairman and member.
About Céline Fantin
Céline Fantin, who graduated from EM Lyon and KEDGE, began her career at KPMG and spent 10 years auditing listed companies in the health and new technology sectors. She then joined bioMérieux Group (In Vitro Diagnostics) until 2017 as VP of Internal Audit, Risks, and Compliance, where she created these activities and carried out consulting missions in strategy, crisis management, and transformation; activities that she also developed within Institut Mérieux, in the biotechnology sector. She is currently Chairman of Fantinnov SAS, a consulting firm specializing in strategy, transformation, and investment for executives of family-run companies and startups. Céline Fantin is also a director of the listed company ORAPI Group (professional hygiene), Chairman of the Audit Committee, and a member of the Risk Committee and the CSR Committee.
Céline Fantin said: “It is with great enthusiasm that I join the Board of Directors of Lysogene, whose innovative and ambitious project brings hope for improving the understanding of CNS diseases and the lives of young patients”.
About Michel Picot
Michel Picot, an HEC graduate, also started his career in audit at Peat Marwick Mitchell & Co. before holding several executive positions in the industry, including Deputy CEO of Vivendi Telecom International until 2004. He is currently Chairman of Advest SAS, a strategy, management, and investment consulting firm specializing in technology companies. Michel Picot is also a director of Eurobio Scientific (formerly Diaxonhit), a publicly traded biotechnology company specializing in diagnostics. He is a member of the Investment Committee and the Risk and Audit Committee of Invensys Pension Sch. He is also a member of the Advisory Boards of Bpifrance under the ETI Accelerator programs.
Michel Picot said: “Lysogene’s mission and ambitions are an excellent motivation to join the Board of Directors of the Company. The quality of the Board I am joining, the management, and the teams of Lysogene are fully in line with these ambitions and I am very honored to take part with them in the Lysogene adventure”.
About Lysogene
Lysogene is a gene therapy company focused on treating orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable the delivery of gene therapies to the CNS to treat lysosomal diseases and other disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA is ongoing. An adaptive clinical trial in GM1 gangliosidosis is also ongoing. Lysogene is also developing an innovative AAV gene therapy approach for the treatment of Fragile X syndrome, a genetic disease related to autism. The Company also entered into an exclusive worldwide license agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for a novel gene therapy candidate for neuronopathic Gaucher disease and Parkinson’s disease with GBA1 mutations.
For more information, visit

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.